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ABSTRACT 
 
The Cost of Mupirocin Resistance in Staphylococcus                                                            
 
by 
Susan D. Reynolds 
 
Control of antibiotic resistance in bacteria is based on the concept that resistance incurs a fitness 
cost in non-selective conditions.  Fitness costs were assessed for low- and high-level mupirocin 
resistance in locally-derived Staphylococcus aureus and S. epidermidis.  Costs of resistance were 
assessed in pure cultures by comparing growth curve characteristics and in mixed culture as the 
proportion of resistant cells surviving.  Costs were not present in comparisons of growth rates 
among groups of naturally-occurring isolates from the different resistance categories.  However, 
in S. aureus, growth rates within resistance categories differed by approximately 30 – 90%.  
Among near-isogenic pairs of strains, fitness costs ≥10% were present in three of eleven pairs 
under pure culture and in six of eleven pairs under competition in mixed culture.  Differences in 
intrinsic growth rates could easily mask fitness costs of the magnitudes observed.  Thus, clinical 
outcomes also depend on whether there is a mixed infection and if so, on the growth rates of 
strains present. 
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CHAPTER 1 
      INTRODUCTION 
 
Staphylococcus aureus is a frequent component of the human microflora being found 
primarily on the skin and in the nares.  In healthy individuals, S. aureus does not usually cause 
infection but, when skin or the membranes in the nares become compromised through trauma 
such as injury or surgery, S. aureus can be introduced into deeper tissues with the potential of 
becoming pathogenic.  S. aureus is the causative agent for impetigo and other skin infections; 
however, it can also manifest as more serious complications such as osteomyelitis and scaled 
skin syndrome (Holmes et al. 2005).  S. aureus is also a common nosocomial pathogen (i.e., a 
pathogen that is acquired during a hospital stay) that tends to infect patients that are already 
immune compromised.  Methicillin-resistant S. aureus strains (MRSA) have acquired resistance 
to a notable portion of the β-lactam class of antibiotics and present a major treatment 
complication for physicians (Ip et al. 2005).  More recently, S. aureus has become a public 
concern with the emergence of community acquired methicillin-resistant S. aureus (CA-MRSA) 
(Takizawa et al. 2005) that is more invasive and genetically different from healthcare associated 
MRSA. 
 
Antibiotics were first introduced for therapeutic use following the discovery of penicillin 
by Alexander Flemming in 1928, but penicillin-resistant organisms were soon reported.  The 
emergence of antibiotic resistance has limited the treatment options available.  In a 16-year study 
(1986 – 2002) focusing on the evolution of antibiotic resistance in Staphylococcus.  Cuevas et al. 
(2004) reported that resistance levels in S. aureus increased with respect to 6 of the 13 antibiotics 
used in the analysis and resistance to penicillin remained stable throughout the 16 year study at 
approximately 95%.  In coagulase-negative Staphylococcus, resistance levels increased with 
respect to 8 of the 13 antibiotics tested.  
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 Suggested Strategies for Managing Resistance 
 
Major treatment complications can accompany an increase in antibiotic resistance in 
pathogens, including an increase in morbidity and/or mortality rates.  Thus, economic costs of 
health care interventions to combat resistance can be significant.  Carbon et al. (1999) reported 
that the difference in treating an methicillin-sensitive S. aureus (MSSA) infection compared with 
that of an MRSA infection was $ 40,090 (MSSA $24,280, MRSA $64,370) a 250% increase.  A 
common strategy to combat antibiotic resistance is the development of new antibiotics, thereby 
providing health care professionals with an arsenal of drugs with which to fight infectious 
diseases. 
 
An alternative strategy to combat resistance is to actively manage the resistance to the 
antibiotics already in use.  There are three common practices that have been implemented.  The 
first strategy is referred to as “judicious usage” (Gordts et al. 2000).  Judicious usage is 
implemented by individual physicians and is contingent upon the physicians abiding by the 
assumptions that; 1) the antibiotic will be used for target prophylaxis versus general prophylaxis, 
2) the infection being treated is bacterial in nature and, 3) the bacteria responsible for the 
infection is susceptible to the antibiotic being used.  The second management strategy is referred 
to as “administrative control” (Walker et al. 2004).  This policy can be very effective when 
implemented in an environment such as a hospital where there is a hierarchical administrative 
structure or in socialized countries in which medicine in under government control.  Physicians 
are prohibited from prescribing an antibiotic in question unless given permission from an 
infectious disease physician.  The third strategy is termed “antibiotic cycling” in which an 
antibiotic is used until resistance becomes apparent, at which time usage will be decreased and 
replaced with an alternative antibiotic until resistance to the first antibiotic is no longer detected 
allowing that antibiotic to once again be used (Brown et al. 2005).   
 
All three management strategies are based on the assumptions that there is a fitness 
“cost” to the acquisition and maintenance of the resistance trait.  The “cost” associated with 
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antibiotic resistance may be due to either the altering of basic cell processes such as cell wall 
synthesis, DNA replication, or protein synthesis but may also be attributed to the maintenance of 
extra-chromosomal DNA as in the case of a plasmid.  The cost of antibiotic resistance is most 
typically manifested and assayed as a reduction in growth rate (Lenski 1997).  When patients, 
infected with sensitive bacterial strains are treated with an appropriate antibiotic, the antibiotic 
action results in eradication of the infection.  However, widespread antibiotic therapy also 
introduces selective pressure that provides an environment capable of facilitating the acquisition 
of resistance by means of spontaneous mutation, horizontal gene transfer via conjugation 
(transfer of genetic material from cell to cell), natural transformation (uptake and incorporation 
of homologous DNA into the host genome), or transduction (introduction of genetic material via 
a bacteriophage) (Neidhardt et al. 1990).  If the acquisition of resistance incurs a cost, once the 
selective pressure is removed, sensitive strains would be able to outgrow resistant strains and 
therefore, eliminate the resistant sub-population.  While mutation/selection balance may allow 
for effective management of resistance, it has been shown that with continued selection (i.e., 
exposure to antibiotics) bacteria may have the ability to acquire compensatory mutations that 
mitigate the cost of resistance (Schrag and Perrot 1997).  To compound the problem, there is 
evidence to suggest that in many cases where multiple mutations result in the same resistance 
phenotype, those mutations incurring either a low or no–cost will be selected for and proliferate 
in the population (Hurdle et al. 2004).  In each of these cases, management strategies would not 
be effective.  Because of the key role of fitness costs in influencing the outcome of antibiotic 
selection, an investigation into the fitness cost of mupirocin resistance was the focus of my 
research. 
 
Mupirocin 
 
The antibiotic mupirocin occurs naturally as a fermentation product of Pseudomonas 
fluorescens (Chain et al. 1977).  Mupirocin intercalates into the Rossman fold domain of the t-
RNA synthetase enzyme, preventing isoleucine from binding to the isoleucyl t-RNA synthetase 
and thereby inhibiting protein synthesis (Hughes et al. 1978).  
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Bacteria can acquire resistance to mupirocin by two genetic pathways.  One is via a 
chromosomal mutation in the native ileS gene that encodes for the isoleucyl t-RNA synthetase.  
Resistance occurs when there is a conformational change in the Rossman fold domain that 
prevents the intercalation of the mupirocin but allows for the binding of the amino acid 
isoleucine, thereby allowing protein synthesis to proceed.  The chromosomal mutation confers 
low-level resistance, as defined by an MIC, minimum inhibitory concentration (i.e., the 
minimum concentration of an antibiotic that prevents visible growth).  Chromosomal mutations 
can lead to MICs of >8 µg/mL - < 256 µg/mL.  It has been suggested that low-level resistance 
increases the failure rate for nasal decolonization of methicillin-resistant S. aureus (MRSA) 
(Hurdle et al. 2004).  High–level resistance is conferred by the acquisition of the mupA gene, 
most often reported as plasmid-borne (Morton et al. 1995).  The mupA gene encodes an 
additional isoleucyl t-RNA synthetase gene originally derived from an unknown species but not 
historically found in staphylococci (Gilbart et al. 1993).  The additional gene encodes for a 
different protein from that of the native protein but one that is functionally similar, that is, the 
enzyme is an isoleucyl-tRNA synthetase.  The mupA encoded isoleucyl-tRNA synthetase confers 
resistance to mupirocin but allows the binding of the amino acid isoleucine, thereby allowing 
protein synthesis.  Clinically, high-level mupirocin resistance allows for the proliferation of a 
MRSA infection in the presence of the antibiotic. 
 
Mupirocin provides a particularly appropriate system for the study of the cost of 
resistance because it was recently introduced clinically, (in the 1980’s) and because of the novel 
target.  Thus, it is most likely that any resistance observed in the study isolates is most likely due 
to the selection pressure of this particular antibiotic and not the result of previous antibiotic 
exposure or cross resistance.   
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Previous Studies 
   
A fitness cost associated with high-level mupirocin resistance has yet to be studied 
however, Hurdle et al.  (2004) investigated the fitness cost of low-level mupirocin resistance in 
S. aureus using both in vitro and in vivo methods.  Mutations V588F and V631F are 
chromosomally encoded in the ileS gene and are found in the ATP-binding domain of the 
Rossman fold region.  These mutations are first-step mutations that are achieved by plating 
strains onto media containing the antibiotic at a concentration that lies between the MIC and the 
MPC, mutant prevention concentration (i.e. the lowest concentration of an antibiotic that 
prevents bacterial colony formation from a culture containing 1010 CFU).  This method of mutant 
selection produced mutants at a frequency (7.2 +/- 0.9 x 10 -8) that is consistent with single 
mutational events (i.e. first-step mutations).  Mutations V588F and V631F confer low-level 
resistance and are widely distributed among clinical isolates.  A mixed culture competition assay 
and a mouse wound abscess infection model were used to assess the fitness cost.  There was no 
significant fitness cost associated with either of these mutations either in vitro or in vivo.   
 
Mupirocin was introduced locally at the James H. Quillen Veterans’ Affairs Medical 
Center (VAMC) in 1990.  Many patients at this facility have chronic health problems and many 
are immune compromised.  Because of the at-risk patient population, carriage of methicillin-
resistant S. aureus (MRSA) can be considered a potential source of infection.  Therefore, 
eradication of colonizing MRSA in patients in the facility was deemed desirable.  Mupirocin was 
used prophylatically to decolonize the nares of those patients who were carriers of MRSA upon 
their admission to the VAMC.  In the four years after the introduction of mupirocin, high–level 
resistance increased from less than 10% to > 30% of the MRSA recovered from VAMC patients 
(Walker et al. 2004).  At that point, the management policy of “judicious usage” was 
implemented, but this was not effective in notably reducing resistance.  Both the proportion of 
low-level and high-level resistant MRSA continued to increase.  Isolates that were collected 
during the time period in which mupirocin was being used were categorized into eras according 
the mupirocin usage policy and incidence of resistance to mupirocin.  Era 1 represents the 
introduction of mupirocin.  Eras 2 and 3 correspond to when resistance was highest and Eras 4 
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and 5 correspond to when mupirocin usage had dramatically declined due to administrative 
control.  Era 6 represents November to December of 2002, which followed the study of 
administrative control.  At the end of Era 3, when resistance was highest, the management 
strategy of “administrative control” was introduced, and was very successful in reducing the 
incidence of both low- and high-level resistance.  By 2001, (Era 5) both forms of resistance had 
been reduced to ≤ 10% (Walker et al. 2004).  The reduction observed would suggest that there is 
a cost to both low-level and high-level mupirocin resistance.   
 
To determine whether mupirocin could effectively be used again at the VAMC we looked 
at possible reservoirs for mupirocin resistance that might provide a means of transfer back into 
the S. aureus population.  The most logical source of resistance would be another 
Staphylococcus species.  One of the most common species of Staphylococcus is S. epidermidis, 
which is also a typical component of human microflora primarily colonizing the skin and is less 
pathogenic than S. aureus.  Staphylococcus epidermidis has the potential to serve as a reservoir 
because it fulfills the following criteria.  S. epidermidis shares a common niche with S. aureus in 
that both may be found in the human nares (Shobha et al. 2005) and S. epidermidis possesses 
antibiotic resistance diversity that is not present in S. aureus.   Finally, in order to serve as a 
reservoir, S. epidermidis must have the ability to transfer the mupirocin resistance to S. aureus.  
To determine if local S. epidermidis could serve as a reservoir, a series of conjugative 
experiments was performed (Udo et al. 1998; Morton et al. 1995).   
 
A proportion of healthcare workers at the VAMC also work at the Johnson City Medical 
Center (JCMC).  To determine whether similar trends in resistance would be observed at the 
JCMC, isolates from both facilities were analyzed over time for level of resistance.  Mupirocin 
resistance declined at the JCMC as well as at the VAMC in MRSA.  The question remained 
whether or not mupirocin resistance had been eradicated from the population to a point that the 
drug could be effectively prescribed again.  The current level of mupirocin resistance in S. 
epidermidis was determined from both the VAMC and the JCMC and low-level and high-level 
resistance was significantly greater in S. epidermidis than in the current populations of S. aureus.  
Unfortunately, we did not have historical data for S. epidermidis and were, therefore, unable to 
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infer the trend in resistance for this species.  However, the observation that mupirocin resistance 
had not been effectively eradicated from the current S. epidermidis population at either facility 
suggests S. epidermidis is not incurring a significant cost of mupirocin resistance.. 
 
 
In the first experimental design, S. aureus was used as a donor to transfer its high-level 
resistance to other strains of S. aureus as well as to strains of S. epidermidis.  It was possible to 
transfer high-level resistance to both S. aureus and S. epidermidis strains.  The second 
experimental design used a strain of S. epidermidis as the donor and other strains of S. 
epidermidis or S. aureus as potential recipients.  There was not evidence to support the transfer 
of high-level mupirocin resistance to either S. aureus or S. epidermidis from S. epidermidis.  The 
third experimental design used a S. epidermidis transconjugant, which had just received the 
mupA gene from S. aureus, to serve as a donor.  The transconjugant strain of S. epidermidis was 
capable of transferring the gene to both S. aureus and S. epidermidis strains (Barnard 2006).  
Possible explanations would be that perhaps the high-level resistance in S. epidermidis may be 
encoded on the chromosome or that it may exist on a non-transmissible plasmid (Udo et al. 
2003) 
 
With continued exposure to selective pressure bacteria will maintain the resistance genes 
and often may acquire compensatory mutations that mitigate the “cost” associated with 
resistance.  Besier reported in 2005 that a second-site mutation in elongation factor G 
compensated for the fitness burden incurred by fusidic acid resistance (due to a mutation 
occurring in the fusA gene of elongation factor G) in S. aureus.  
 
In Salmonella typhimurium the acquisition of streptomycin resistance results in a 
decreased rate of protein synthesis, bacterial growth, and virulence.  However, in 77 out of 81 
low-level resistant strains analyzed, compensatory mutations in the target genes had occurred 
without any loss in resistance (Maisnier-Patin et al. 2002).  Even more surprising was the 
discovery that when rifampin-resistant E.coli was analyzed under antibiotic selection both the 
fitness level increased and the resistance level increased (Reynolds, 2000).  In contrast, 
 14
Wichelhaus (2002) that a variety of mutations in the rpoB gene conferring high-level rifampin 
resistance were associated with varying levels of cost.  However, the mutation occurring at 
amino acid position 481 exchanging histidine for asparagines and conferring low-level 
resistance, was not associated with a cost in S. aureus.   Thus, a review of the literature revealed 
that fitness costs are not universal and are specific to particular antibiotics and genera 
combinations.  
 
                                                 Proposed Research 
 
The goal of the study was to assess the “cost” of mupirocin resistance in Staphylococcus, 
with an emphasis on S. aureus.  Several questions were addressed, 1) does the acquisition of the 
mupA gene, conferring high-level resistance, have a detrimental affect on the fitness of the 
bacteria? 2) has the cost of mupirocin resistance changed over time in locally-derived strains? 3) 
is the cost of resistance different in S. epidermidis. 
 
The primary hypothesis, based on a previous study (Walker et al. 2004), was that the 
mupA gene, which is usually carried on a plasmid (Gilbart et al. 1993), causes a decrease in 
growth rate in staphylococci and, therefore, imparts a fitness cost to the organism.  The second 
hypothesis was that when S. aureus first acquired the mupA-mediated resistance there was a cost 
but over time, compensatory mutations have accumulated to mitigate the cost of the resistance.  
Therefore, a decrease in the cost can be expected over time.  The third hypothesis is that there 
will be a cost associated with the acquisition of the mupA gene in S. epidermidis.   
 
The first prediction is that the growth rates of the strains that have high-level mupirocin 
resistance will be significantly lower compared to those strains that are mupirocin-sensitive 
when analyzed in an environment with no selective pressure.  The second prediction is that a 
significant decrease in growth rate of the strains that have high-level resistance compared to 
those that are sensitive will be observed when analyzing those strains isolated when the mupA 
plasmid was first acquired by the organism.  The third prediction is that this same phenomenon 
will be observed in S. epidermidis. 
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To test these hypotheses the growth rates of a group of naturally-occurring sensitive, low-
level, and high-level resistant strains of S. aureus and S. epidermidis were analyzed in vitro in 
pure liquid culture using fitness estimators based on growth curves.  The sample of isolates 
spanned a 14-year time period that ranged from the introduction of mupirocin through 2004 at 
VAMC.  This sample provided an opportunity for studying changes in the cost of resistance over 
time that may have occurred.  In addition, a head to head paired mixed liquid culture, 
competition assay was used to assess the cost of the mupA gene in near-isogenic pairs of strains.  
There were two types of near isogenic pairs generated for the assay.  First were mupA gene cures 
generated from naturally-occurring, high-level resistant S. aureus and S. epidermidis strains that 
were cured of their high-level resistance.  Transconjugants were the second type of isogenic 
pairs generated using naturally-occurring, sensitive S. aureus and S. epidermidis strains into 
which high-level resistance was transferred via filter matings with high-level resistant strains.  
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                                                                    CHAPTER 2 
MATERIALS AND METHODS 
 
Curing of mupA Gene 
 
A group of naturally-occurring, locally-derived, clinical, high-level mupirocin-resistant 
strains of S. aureus and S. epidermidis were subjected to a heat-curing procedure in an attempt to 
generate a group of near-isogenic pairs. They are considered near isogenic because in some pairs 
there is evidence that other antibiotic resistances cured in conjunction with mupirocin resistance.  
Since prior research (Udo et al. 1998; Morton et al. 1995) reported that the mupA gene was 
plasmid-borne, a method designed to cure plasmids through heat stress was used to generate 
near-isogenic pairs. When successful, these isogenic pairs consisted of a high-level mupirocin-
resistant progenitor strain and its sensitive derivative that had been cured of its mupirocin 
resistance.  Each strain that was used in the heat-cure procedure was initiated from -80°C freezer 
stocks of high-level resistant strains.  Clinical cultures of MRSA sometimes represent mixtures 
of strains.  Therefore, strain purity was confirmed as follows.  Aliquots of freezer stocks were 
spread on tryptic soy agar (TSA) plates and incubated overnight at 37°C.  Ten isolated colonies 
of each strain were transferred first to TSA plates and then to plates containing mupirocin at 125 
µg/mL (mup125) to prevent carryover of the antibiotic to the non-selective plate.  Mupirocin 
powder was a gift from Glaxo SmithKline, Research Triangle, Raleigh, N.C. to Dr. Elaine 
Walker.  All plates containing antibiotics were incubated at 35°C unless otherwise noted and all 
non-antibiotic (non-selective) plates were incubated at 37°C.  Resultant colonies that grew on 
both selective and non-selective plates, (potential high-level resistant progenitors) were 
expanded on a second TSA plate to be tested for mupirocin susceptibility using the Etest method. 
Colonies that had an MIC ≥ 256µg/mL indicated high-level resistance presumably conferred by 
the presence of the mupA gene.  After confirmation of high-level mupirocin resistance, cultures 
were stored frozen at -80°C to be used for future experiments. 
 
Sensitive derivatives of mupirocin-resistant strains were generated by serial passage of 
liquid cultures grown under heat stress, as follows.  Aliquots of frozen cultures of each 
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progenitor strain were used to inoculate 5 mL of tryptic soy broth (TSB) and incubated overnight 
at an elevated temperature of 42°C.  This temperature places the bacteria under heat stress and 
that can enhance plasmid loss (May et al. 1964).  Each strain was cultured at 42°C for a total of 
either 4 or 10 days.  Following each overnight incubation, an aliquot of culture of each strain 
was Gram stained to ensure purity of the cultures.  Prior to the next overnight incubation, 100 µl 
of each strain was transferred to fresh 5 mL of TSB.  Following the final day of incubation, a 
loopful of broth culture was spread on TSA and incubated overnight.  Between 20 and 100 
individual, isolated colonies were transferred to both TSA and mup125 plates and incubated 
overnight at 37°C and 35°C, respectively.  Colonies that did not grow on the mup125 plates 
(potential cured derivative strains) were rescued and expanded on TSA plates.  Colonies can be 
rescued when the antibiotic has a bacteristatic effect on the bacteria verses a bactericidal effect.  
Rescuing is accomplished by swabbing the area in which the colony was inoculated (area may 
appear to have no or very slight growth) and then transferring those cells to a non-selective 
media.  Following incubation, each potential derivative was tested for mupirocin susceptibility 
by Etest to confirm sensitivity.  Strains with an MIC ≤ 32µg/mL were considered cured of the 
high-level resistance gene and were frozen at -80°C to be used for fitness cost analysis assays.   
 
Transconjugants 
 
Near isogenic progenitor/transconjugant pairs of isolates were created by conjugative 
transfer of the mupA gene from a mupirocin-resistant donor to a sensitive recipient.  This 
procedure resulted in near isogenic pairs of strains (i.e. there was evidence that other antibiotic 
resistances co-transferred with mupirocin resistance) comprised of the sensitive progenitor strain 
and the resistant recipient.  Five such pairs were used for cost analysis assays.  Prior to the 
conjugation procedure the resistance phenotypes of prospective donor and recipient strains were 
confirmed by spreading each strain on a plate containing combinations of antibiotics.  All donors 
were mupirocin-resistant, rifampin-sensitive, and fusidic acid-sensitive (mupR, rif S, FAS).  All 
recipient strains were marked with rifampin and fusidic acid resistances.  After confirming donor 
and recipient phenotypes, each was used to inoculate 10 mL of TSB, followed by incubation 
overnight at 37°C.  Donor cultures were grown in TSB with mupirocin at a concentration of 150 
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µg/mL to ensure retention of the mupirocin resistance gene.  The recipient cultures, following 
incubation, were diluted 10-6, -7, and -8 to estimate the number of potential recipient cells in each 
mixture. Excess mupirocin was removed from the donor cells prior to mating, as follows.  
Following incubation, donor cells were washed two times in TSB by centrifugation 1500 x g for 
5 minutes, the supernatant removed, and cells resuspended in fresh TSB to remove excess 
mupirocin.  The donor cultures and recipient cultures were mixed at a 1:3 ratio respectively, 
resulting in a final volume of 4 mL.  The donor/recipient mixture was then transferred to a 
Millipore® filter (0.45µm) using a vacuum filtration device.  Filters were placed on a TSA plate 
and oriented with bacteria on top, without inversion, overnight at 37°C.  Following incubation, 
the bacteria were washed off of the filter into 1 mL TSB by vortexing.  A 25 µl aliquot of each 
potential transconjugant strain was spread onto a selective Mueller-Hinton plate containing 
mupirocin at (32 µg/mL), rifampin (32 µg/mL), and fusidic acid (15µg/mL).  This three 
antibiotic combination would eliminate donors and recipients and therefore select only for 
transconjugants.  Following incubation at 35°C potential transconjugants were single colony 
picked to another triple antibiotic plate to confirm resistance.  This selection step would 
minimize any false transconjugants resulting from antibiotic depletion caused by background 
growth.  One transconjugant colony from each successful cross was then grown on TSA and its 
purity was confirmed using Gram stain, catalase, and coagulase tests. 
 
                                                            Cost Analysis Assay
 
Each strain analyzed originated from freezer stocks of strains showing varying levels of 
susceptibility to mupirocin (susceptible < 4 µg/ml; low-level resistance 4-256 µg/ml; high–level 
resistance > 256 µg/ml; Table 3).  Aliquots of each strain were spread on TSA plates and 
incubated overnight at 37°C.  The resultant growth from the TSA plates was used to inoculate 10 
mL of TSB the following day and was incubated overnight at 37°C.  Following incubation, 5 mL 
of 0.85% NaCl was inoculated with cells until a density equal to that of a 0.5 McFarland 
Standard had been reached.  A 0.5 McFarland standard is considered equivalent to1 x 108 
cells/mL.  
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The cost of resistance was estimated from growth curves generated by microtiter plate 
cultures in a dynamic spectrophotmetric analyzer (Bioscreen C).  Each sample well contained a 
total of 200 µL. Each strain was run in triplicate at each of three different mupirocin 
concentrations: [0, 8, and 1024 µg/mL].  One well of only TSB was used as a negative control.  
The Bioscreen C microtiter plate analyzer was programmed to shake every 3 minutes for 10 
seconds and the optical density of each sample was recorded using a 600 nm filter every 10 
minutes for a total of 48 hours.  A graphical depiction of the growth curve for each sample was 
extrapolated by the program using the absorbance readings.  Strains that were marked with 
rifampin and fusidic acid (i.e., resistances that are chromosomally-encoded and reported to incur 
a fitness cost) (Nagaev et al. 2001, Wichelhaus et al. 2002) were compared to their 
corresponding susceptible strains and served as a reference for the sensitivity of the assay (Table 
3). 
 
The doubling time for each strain was estimated from individual growth curves that were 
generated from optical density readings.  Strain-specific doubling times were calculated as: 
doubling time = log10(final OD) – log10(initial OD) / log2 (time in minutes) from the linear 
portion of the curve when visualized on a semilog plot.  The linear portion of the growth curve 
was determined by maximization of the linear regression coefficient (R2).  In addition, the area 
under the curve was recorded for each strain at 24 hours.  This measurement provided a second 
measure of fitness because it takes into account the length of the lag phase, slope of the log 
phase, and the time at which stationary phase was reached, factors that are not accounted for in 
fitness estimates from doubling times.  
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Paired Competition Assay 
 
The near-isogenic pairs of strains used for the competition experiments originated from 
frozen stock cultures that were generated from the heat cure procedures and conjugation 
experiments.  Aliquots from corresponding freezer stocks were spread onto TSA and incubated 
overnight at 37°C.  Following incubation, cells were added to 0.85% NaCl solution until the 
density was equivalent to a # 3 McFarland standard (9x108 cells/mL).  Using Bioscreen C, a 
single optical density reading was taken for each bacteria solution to ensure similar cell 
densities.  An aliquot of 100µL from each isogenic pair was combined in a microfuge tube and 
vortexed to mix.  An aliquot of 100 µL from the above mixture (i.e. resistant progenitor and 
respective sensitive derivative) was used to inoculate 10 mL of TSB and was incubated 
overnight in a 37°C water bath.  The proportion of each population within the mixed culture was 
determined from CFU counts of serial dilution plates.  To estimate the proportions of resistant 
and sensitive cells, each dilution was spread on both selective media, containing mupirocin 32 
µg/mL and on non-selective TSA media.  For each mixed culture, colony counts were taken at 0, 
24 hours, and 72 hours.  The resistant population was determined as a proportion of the total 
population by dividing the total number of resistant colonies by the number of colonies in the 
total population (i.e. resistant population / total population x 100 = percentage of resistant 
bacteria in the population).  
 
    Statistical Analysis 
 
All statistical analysis was conducted using Minitab software (Minitab, Inc., State 
College, PA). The data pertaining to the naturally-occurring S. aureus and S. epidermidis strains 
were analyzed using a one-way ANOVA.  A one-way ANOVA analysis is used to compare 
categories of data and was used specifically to assess differences between resistance categories.  
Then, separate one-way ANOVA analyses were conducted to test for variance among strains 
within resistance categories.  The heat cured strains, transconjugants, and control strains were 
analyzed using a paired t-test.  
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                                                          CHAPTER 3 
 
                                                                        RESULTS 
 
                                                               Curing of mupA Gene 
 
Heat curing of mupirocin resistance was attempted on a total of 34 Staphylococcal ssp. 
strains (29 S. aureus and five S. epidermidis).  After an initial round of attempted cures, two out 
of nine (22%) strains were cured.  Therefore, both the length of time and the total number of 
colonies from each strain screened were increased from four to ten days and from 20 to at least 
50 colonies as noted (Table 1).  In spite of the increase in curing time and total colonies screened 
the cure rate remained relatively stable, with cures of four of 20 (20%) subsequent strains 
attempted.  A total of six S. aureus strains were successfully cured of their mupA gene to 
generate sensitive derivatives.  One S. epidermidis strain was successfully cured of its mupA 
gene; however, it was found to have low-level resistance (MIC = 128 µg/mL), which has been 
shown to be chromosomally encoded (Hurdle, et al. 2004).  The cured S. epidermidis strain was 
not used in the cost analysis assay.  Table 2 gives a complete list of the resistance phenotypes 
(other than mupirocin) that were lost through the curing process.  Gentamicin resistance was 
most commonly lost (three of seven) in association with curing of the mupA gene.   
An effect of isolate time-of-recovery was apparent when the curing data were analyzed.  
Curing was significantly more successful during the era 1 with a cure rate of 75%.  Era 1 
corresponds to the introduction of mupirocin into the population.  The other eras had a combined 
cure rate of 12% (Table 1).  A heterogeneity chi-square analysis showed the cure rate for Era 1 
was significantly greater (χ2 = 9.46, df = 3, p = 0.024) than the cure rate of eras 2-4.  
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Table 1.  Cures of Mupirocin Resistance.  Bacterial strains, cure conditions, and cure rates for 
which mupirocin curing was attempted.  Era 1: August 1990 – August 1993; Era 2: September 
1993 – December 1995; Era 3: June 1996 – February 1999; Era 4: March 1999 – April 2000; Era 
5: May 2000 – May 2001; Era 6: November – December 2002.  “Sa” denotes S. aureus.  All S. 
aureus that lost high-level resistance were cured to sensitivity.  * Staphylococcus epidermidis 17 
was cured to low-level resistance with an MIC = 128 µg/mL.  
 
Strain  Era 
Number of Treatment 
Days 
Number of 
Colonies Screened 
Number of 
Sensitive Colonies 
% 
Cured 
Sa 1593 1 4 20 1 
Sa 1480 1 10 50 0 
Sa 1484 1 10 50 2 
Sa 1589 1 10 50 1 
75% 
Sa 1858 2 4 20 0 
Sa 2549 2 4 20 0 
Sa 1680 2 10 50 0 
Sa 1770 2 10 50 4 
Sa 1706 2 10 50 0 
Sa 1724 2 10 50 0 
Sa 1754 2 10 50 0 
Sa 3475 3 4 20 0 
Sa 3780 3 4 20 0 
Sa 4323 3 4 20 0 
Sa 5519 3 4 20 0 
Sa 2825 3 10 50 0 
Sa 2885 3 10 50 0 
Sa 3147 3 10 50 0 
Sa 3388 3 10 50 0 
Sa 3431 3 10 50 0 
Sa 3447 3 10 50 0 
Sa 3651 3 10 50 6 
Sa 4431 3 10 50 0 
Sa 4907 3 10 50 0 
Sa 5068 3 10 50 0 
Sa 5554 3 10 50 0 
Sa 5592 4 4 20 0 
Sa 5965 4 4 20 20 
12% 
Sa 5579 4 10 50 0  
S. epidermidis 7 6 10 50 0 
S. epidermidis 17 6 10 50 1* 
S. epidermidis 27 6 10 50 0 
S. epidermidis 34 6 10 50 0 
S. epidermidis 35 6 10 50 0 
20% 
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Table 2. Antibiotic Resistances and Susceptibilities for Each Isogenic Pair.  Changes in 
resistance attributed to either acquisition of the mupA gene via conjugation or loss of the mupA 
gene via curing are highlighted.  Progenitor / derivative pairs are shown on adjacent rows. “Sa” 
denotes S. aureus and “Se” denotes S. epidermidis. “TC” denotes transconjugant.  Antibiotics: 
Mupirocin (MUP), Tetracycline (TE), Erythromycin (E), Gentamicin (GM), Rifampin (RA), 
Sulfamethoxazole/Trimethoprim (SXT), Chloroamphenicol (C), Clindamycin (CC), and 
Ciprofloxacin (CIP).  
 
Strain MUP TE E GM RA SXT C CC CIP 
Sa 1589-1 R S R R S S S R R 
Sa 1589-48 S I R S S S S R S 
          
Sa 1480-1 R S R R S S S R R 
Sa 1480-4 S I R R S S S R R 
          
Sa 3651-9 R S R R S S S R R 
Sa 3651-37 S S R S S S S R R 
          
Sa 1770-1 R S R S S S S R S 
Sa 1770-24 S S R S S S S R S 
          
Sa 5965-10 R S I R S S S I S 
Sa 5965-1 S S I S S S S S S 
          
Sa 1858-8 R S S S S R S S I 
Sa 1858-13 S S S S S R S S R 
          
Se 17 R S R S S R S R R 
Se 17-10 S S R S S I S R R 
                    
Sa 2782-22 S S R S R S S R R 
Sa 2782-22 TC R S R R R S S R R 
          
Se 22B1 S S S S R S S S S 
Se 22B1 TC R S S R R S S S S 
          
Se 5A1 S S S S R S S S S 
Se 5A1 TC R S S R R S S S S 
          
Se 27A2 S S S S R S S S R 
Se 27A2 TC R S S R R S S S I 
          
Se 30B1 S S E S S I S S R 
Se 30B1 TC2 R S E I S R S S R 
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Transconjugants 
In filter-mating assays of locally-derived strains, S. aureus donors could transfer the 
mupA gene to both S. aureus and S. epidermidis in several cases.  In contrast, when S. 
epidermidis was used as a donor, it was not possible to transfer the mupA gene to either a S. 
aureus or S. epidermidis recipient. However, if a S. epidermidis transconjugant (i.e. a strain that 
had received the mupA gene from an S. aureus strain) was used as a donor, the mupA gene could 
be transferred to both S. aureus and S. epidermidis recipients (Barnard 2006).  Table 2 gives a 
complete list of antibiotic resistance phenotypes transferred in association with mupirocin.  
Gentamicin resistance was most commonly transferred with mupirocin resistance.  For both 
mupirocin-resistance-cured strains and transconjugants there was a strong, but not absolute 
association between gentamicin resistance and mupirocin resistance.  Three of four cured strains 
lost both mupirocin resistance and gentamicin resistance and four of five transconjugants gained 
both mupirocin resistance and gentamicin resistance. 
 
 
Cost Analysis Assays 
 
Naturally-Occurring Strains
 A total of 36 naturally-occurring strains comprised of 25 S. aureus and 7 S. epidermidis 
of varying levels of mupirocin resistance were included in the cost analysis assay.  The cost 
analysis was based on growth curve characteristics of pure strain cultures.  The doubling time for 
each strain was inferred from the linear-most portion of the log phase of the growth curve.  Each 
growth curve was generated using optical density readings.  The average doubling times and area 
under the curve measurements at 24 hours are given in Table 3.  The mean and standard 
deviation for each resistance category within each species are given in Table 4.  Three strains 
resistant to both rifampin and fusidic acid were used to determine sensitivity of the assay.  Only 
one, Se 5A1, showed a significant cost of resistance when assessed using the growth curve 
assays. 
.   
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Strains were assayed under no mupirocin as well as 8 µg/mL and 1024 µg/mL mupirocin. 
Sensitive strains were inhibited by both 8 µg/mL and 1024 µg/mL mupirocin.  High-level-
resistant strains grew equally well under no mupirocin and 8 µg/mL.  At 1024 µg/mL the lag 
phase and log phases were longer compared to growth under no mupirocin and 8 µg/mL.  Low-
level-resistant strains were inhibited by mupirocin at 1024 µg/mL, while their growth was 
arrested (i.e., a longer lag phase and more gradual log phase) under mupirocin 8 µg/mL (Figures 
2 and 3).  
  
 When naturally-occurring S. aureus strains were compared among resistance categories, 
there was not a significant difference in growth rates based on doubling times and areas under 
the curve. However, in S. epidermidis, the low-level-resistant strains were marginally 
significantly slower growing than the high-level-resistant and sensitive strains (Tables 5 and 6).  
In general, there was a significant difference among S. aureus strains within resistance categories 
based on doubling times and areas under the curve.  Among S. epidermidis strains there was a 
significant difference among high-level-resistant strains based on doubling times and among 
low-level-resistant strains based on areas under the curve (Table 7).  However, the magnitudes of 
these differences in S. epidermidis were very small (< 5% difference among strains) when 
compared to ~ 30%-100% inter-strain differences evident in S. aureus. (Figures 4 and 5).  
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Table 3.  Results of the Pure Culture Assays of Growth Rates.  Doubling time and area under the 
curve (AUC) at 24 hours are given in the table as mean values of the replicates of each strain.  
Era 1: August 1990 – August 1993; Era 2: September 1993 – December 1995; Era 3: June 1996 
– February 1999; Era 4: March 1999 – April 2000; Era 5: May 2000 – May 2001; Era 6: 
November – December 2002.  “Sa” denotes S. aureus and “Se” denotes S. epidermidis.  * = 
ATTC Strain.  
 
 
          
     
Strain Era 
Resistance a 
Category 
Doubling  
Time 
(min) 
AUC 
24 hours 
 Naturally-Occurring 
S. aureus         
Sa 1965 2 S 103.6 1112.0 
Sa 5371 3 S 86.5 1016.0 
Sa 5894-L 4 S 114.6 1102.0 
Sa 7A2 6 S 93.9 1107.0 
Sa 8C1 6 S 103.7 1106.0 
Sa 15A1 6 S 88.2 1109.5 
Sa 37A1 6 S 93.5 1162.0 
Sa 44B1 6 S 89.7 1047.0 
Sa 1864 2 L 130.3 1006.5 
Sa 2365 2 L 89.7 1071.0 
Sa 5791-1 4 L 108.9 916.0 
Sa 8B1 6 L 101.1 1127.0 
Sa 1484-H 1 H 86.2 1038.5 
Sa 1680-5 2 H 81.7 1109.5 
Sa 1754-1 2 H 122.9 982.0 
Sa 5579-1 4 H 106.6 946.0 
Sa 5588-L 4 H 82.3 1106.0 
Sa 44A1 6 H 103.9 1062.5 
Sa 44A3 6 H 90.9 1103.0 
 Naturally-Occurring 
 S. epidermidis       
Se 30B1 6 S 99.7 990.5 
Se 40A1 6 S 100.6 962.5 
Se 4C3 6 L 111.1 1030.0 
Se 8B2 6 L 112.4 956.0 
Se 9A1 6 H 105.8 1080.5 
Se 50A1 6 H 98.6 1108.5 
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Table 3 (continued) 
 
mup A Cure Isogenic Pairs         
Sa 1480-1 1 H 86.3 1061.0 
Sa 1480-4 1 S 81.3 1107.0 
     
Sa 1589-1 1 H 103.1 1012.0 
Sa 1589-48 1 S 86.3 895.0 
     
Sa 1770-1 2 H 84.2 959.5 
Sa 1770-24 2 S 82.0 965.0 
     
Sa 1858-8 2 H 156.3 1017.0 
Sa 1858-13 2 S 152.8 1023.5 
     
Sa 3651-9 3 H 93.7 1144.0 
Sa 3651-37 3 S 90.9 1073.5 
     
Sa 5965-10 4 H 110.0 869.5 
Sa 5965-1 4 S 96.8 761.0 
     
Se 17 6 H 95.6 995.5 
Se 17-10 6 L 107.0 1051.0 
 Transconjugant Isogenic Pairs       
Sa 2782-22 RF 3 S 101.1 1015.3 
Sa 2782-22 TC 3 H 98.4 989.3 
     
Sa 22B1 RF 6 S 104.5 1099.7 
Sa 22B1 TC 6 H 101.7 1059.7 
     
Se 5A1 RF 6 S 131.1 884.7 
Se 5A1 TC 6 H 127.8 763.7 
     
Se 27A2 RF 6 S 122.1 960.3 
Se 27A2 TC 6 H 124.0 977.0 
     
Se 30B1 6 S 98.4 919.7 
Se 30B1 TC2 6 H 100.1 921.3 
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Table 3 (continued) 
 
 Rif/FA “Controls” Isogenic Pairs       
Se 5A1  3 S 93.8 1049.0 
Se 5A1 RF 3 R 124.1 787.5 
     
ATCC 35556 * S 105.4 972.5 
ATCC 35556 RF * R 108.7 652.5 
     
Sa 2782-22 3 S 100.2 1113.5 
Sa 2782-22 RF 3 R 101.1 1014.5 
a “S” signifies sensitivity to mupirocin, “L” signifies low-level resistance, and “H” signifies 
high-level resistance. 
 
 
Table 4. Mean and Standard Deviation for Naturally-Occurring S. aureus and S. epidermidis.  
Standard deviation is given in parentheses.  N= number of strains.  
 
 
Doubling 
 Time 
AUC  
 24 Hours 
 S. aureus S. epidermidis S. aureus S. epidermidis S. aureus 
Sensitive 
96.72 
N = 8 
 (9.71) 
100.18  
N = 2 
 (0.658) 
1095.2  
N = 8  
(44.5) 
976.5 
 N = 2  
(19.8) 
208.3 
 N = 8 (44.5) 
      
Low 
107.48 
 N = 4 
(17.11) 
111.17 
 N = 2 
 (0..926) 
1030.1  
N = 4 
(90.6) 
993.0 
 N = 2  
(52.3) 
251.3 
 N = 4 (34.1) 
      
High 
100.63 
 N = 13 
(20.93) 
99.97  
N = 2  
(5.28) 
1031.6  
N = 13 
(78.0) 
1094.5 
 N = 2  
(19.8) 
268.4  
N = 13 
(205.0) 
 
 
 
 
 
 
Figure 1. Growth Curves of Strain Sa1680-5, a Naturally-Occurring High-Level Resistant S. 
aureus Strain.  Assayed under no mupirocin (blue) and mupirocin at concentrations 8 µg/mL 
(green) and 1024 µg/mL (pink).   
 
 
 
 
 
Figure 2.  Growth Curves of Strain Sa 1864, a Naturally-Occurring Low-Level Resistant S. 
aureus.  Assayed under no mupirocin (blue) and mupirocin at concentrations of 8 µg/mL (green) 
and 1024 µg/mL (pink).  
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Table 5.  Results of a One-Way ANOVA Analysis Comparing the Doubling Times among 
Resistance Categories within Naturally-Occurring S. aureus. 
 
Naturally-Occurring 
S. aureus      
Source DF SS MS F P
Resistance Category 2 309 155 0.50 0.613 
Error 22 6794 309   
Total 24 7103    
 
 
Distribution of Doubling Times in S. aureus
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Figure 3.  Distribution of Doubling Times within Resistance Categories in S. aureus.  The mean 
for each group is represented by the horizontal line.  
 
 
Table 6.  Results of a One-Way ANOVA Analysis Comparing the Doubling Times among 
Resistance Categories within Naturally-Occurring S. epidermidis.  
 
Naturally-Occurring 
 S. epidermidis      
Source DF SS MS F P
 
Resistance Category 2 196 98 6.87 0.051 
Error 4 57.1 14.3   
Total 6 253    
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Figure 4.  Distribution of Doubling Times within Resistance Categories in S. epidermidis.  The 
mean for each group is represented by the horizontal line.  
 
 
 
Table 7.  Summary of Analysis of Variance Analyses among Strains within Mupirocin 
Categories in S. aureus and S. epidermidis.  Entries are P-values for separate analyses.  
 
Strain  
Variation 
Doubling  
Times 
AUC  
24 Hours 
Resistance  
Category S. aureus S. epidermidis S. aureus S. epidermidis 
Sensitive 0.001 0.928 <0.001 0.745 
Low 0.3 0.657 <0.001 0.007 
High <0.001 0.043 <0.001 0.04 
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Pure Culture Assay 
 Strains that were cured of mupirocin resistance were compared with their high-level-
resistant progenitors in both the pure culture assays and a mixed culture competition assay for a 
more direct comparison of the cost incurred by the acquisition or loss of mupirocin resistance.  
In pure cultures, cost was calculated as [(doubling time of the sensitive strain – doubling time of 
the resistant strain) / doubling time of the sensitive strain].  A difference of ≥ 10%was 
considered significant.  Doubling times were significantly slower in resistant progenitors 
compared to their cured sensitive derivatives but there was no significant difference based on 
area under the curve (Table 8).  Each strain showed a decrease in doubling time, with the loss of 
the mupirocin resistance (Figure 6).  Only one S. epidermidis strain was able to be cured and this 
strain was cured to low-level resistance (MIC = 128 µg/mL).  Therefore, it was not used for cost 
analyses.  
  
Mixed Culture Competition Assay 
Except for strain Sa 5965, whose cost estimates were varied across replicates and strain 
Sa 1480, all paired competition assay comparisons of the high-level mupirocin-resistant strains 
and their sensitive derivative strains showed evidence of a fitness cost.  Cost was inferred by a 
reduction of ≥ 10 % in the percent of resistant bacteria present in the population (Table 9). 
 
  
Table 8.  Results from Paired t-Test Analysis of Isogenic Pairs. P-values are given for the mupA 
cures (C), strains which have been cured of the mupA gene; transconjugants (TC), strains which 
have acquired the mupA gene via conjugation; and “control” strains, those strains marked with 
chromosomally-encoded rifampin and fusidic acid resistances.  Separate tests were conducted  
for doubling times and area under the curve (AUC).  
 
 
 
Doubling  
Times 
AUC  
 24 Hours 
 C TC Controls C TC Controls 
P-value 0.035 0.422 0.347 0.213 0.232 0.075 
 
 
 
Table 9.  Cost of Mupirocin Resistance in the Isogenic Pairs.  Individual cost or benefit for each 
isogenic pair is given below and is based on differences in doubling time (DT).  “Sa” denotes S. 
aureus and “Se” denotes S. epidermidis.  A “-” indicates cost, while “+” indicates a benefit.  
Cost was calculated as (DTS – DTR)/ DTS, where “S” = mupirocin-sensitive and “R” = mupirocin-
resistant.  A difference of ≥10% indicates a significant cost/benefit associated with mupirocin 
resistance. 
 
Strain Era Resistance Category 
Doubling Time 
(min) Cost/ Benefit 
 Sensitive Progenitor/ Cured Derivative         
Sa 1480-1 1 H 86.3 -6% 
Sa 1480-4 1 S 81.3  
     
Sa 1589-1 1 H 103.1 -19% 
Sa 1589-48 1 S 86.3  
     
Sa 1770-1 2 H 84.2 -2.60% 
Sa 1770-24 2 S 82.0  
     
Sa 1858-8 2 H 156.3 -2.20% 
Sa 1858-13 2 S 152.8  
     
Sa 3651-9 3 H 93.7 -3% 
Sa 3651-37 3 S 90.9  
     
Sa 5965-10 4 H 110.0 -13.60% 
Sa 5965-1 4 S 96.8  
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Table 9 (continued) 
 
 Sensitive Progenitor / Resistant 
Derivative         
Sa 2782-22 RF 3 S 101.1 +2.60% 
Sa 2782-22 TC 3 H 98.4  
     
Sa 22B1 RF 6 S 104.5 +2.60% 
Sa 22B1 TC 6 H 101.7  
     
Se 5A1 RF 6 S 131.1 +2.50% 
Se 5A1 TC 6 H 127.8  
     
Se 27A2 RF 6 S 122.1 -1.50% 
Se 27A2 TC 6 H 124.0  
     
Se 30B1 6 S 98.4 -1.70% 
Se 30B1 TC2 6 H 100.1  
 Rif/FA “Controls”         
Se 5A1  3 S 93.8 -32.30% 
Se 5A1 RF 3 R 124.1  
     
ATCC 35556 * S 105.4 -3% 
ATCC 35556 RF * R 108.7 
 
     
Sa 2782-22 3 S 100.2 -0.80% 
Sa 2782-22 RF 3 R 101.1  
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Figure 5.  Doubling Time by Mupirocin Resistance Status Plot.  Strains cured of high-level 
mupirocin resistance are represented in a graph depicting the change in doubling time attributed 
to the loss of the mupA gene. 
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Transconjugants
 Strains that received high-level mupirocin resistance in filter mating experiments were 
compared to their sensitive progenitor strains in pure culture assays as well as in paired 
competition assays.  Two of the five pairs tested (Se 27A2 and Se 30B1) showed a slight 
increase in doubling times associated with the presence of the mupA gene, while the other three 
strains (Se 5A1, Sa 2782-22, and Sa 22B1) showed a slight decrease in doubling time when 
analyzed in pure cultures (Figure 7).  However, these changes in growth rate were not 
significant, nor were the differences in area under the curve (Tables 8 and 9).  Transconjugant 
strains Se 5A1, Sa 2782-22, and Se 27A2 however, showed a significant cost in paired 
competition experiments (Table 10). 
 
 
Controls 
When analyzed as a group the rifampin and fusidic acid resistant strains did not show a 
significant difference in growth rates in pure culture assays.  However, when they were analyzed 
as isogenic pairs a cost was evident in Se 5A1 based on doubling time and area under the curve 
using the pure culture assay and in both Se 5A1 and Sa 2782-22 using the paired competition 
assay.
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Figure 6.  Doubling Time by Mupirocin Resistance Status Plot.  Graph depicting the change in 
doubling times attributed to the acquisition of the mupA gene via conjugation.  
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Table 10.  Paired Competition Experiment Results. “Sa” denotes S. aureus and “Se” denotes S. epidermidis.  A difference of ≥10% 
indicates a significant cost/benefit.  “-” indicates cost , “+” indicates a benefit.  T = time in hours.  “I” denotes the data was 
inconclusive because one replicate showed a cost and the other a benefit.  The percent change (% change) is calculated as the average 
percent of the resistant population at T = 0 minus the average percent of the resistant population at T= 72.  “TSA” represents the total 
population (number of resistant and sensitive colonies) while “Antibiotic” represents only the resistant sub-population.  All assays 
compare isogenic pairs of strains.  “Cures” refer to a comparison of mupirocin-resistant progenitors and cured sensitive derivatives.  
“Transconjugants” refer to sensitive progenitors and mupirocin-resistant derivatives.  “Controls” refer to sensitive progenitors and 
rifampin- and fusidic acid-resistant derivatives. 
 
 
T = 0 T = 24 T = 72  
Strain  Replicate TSA Antibiotic 
Resistant 
Population     TSA Antibiotic
Resistant 
Population TSA Antibiotic
Resistant 
Population 
% 
Change 
Control               
1          609 231 38% 162 30 18.50% 250 0 0%Se 5A1 
2          571 229 40% 529 96 18% 122 0 0%
-39% 
               
1          608 324 53% 632 85 13% 36 3 8%Sa 2782-22 
2          784 332 42% 622 138 22% 215 18 8%
-39.5% 
               
1          138 41 30% 336 141 42% 236 53 22%ATCC 35556 
2          233 51 22% 159 67 42% 132 39 30%
 0% 
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Table 10 (continued) 
mup A Cures               
1          481 ~368 76% 161 50 31% 268 34 12.7%Sa 1589 
2          263 242 92% 139 33 24% 411 48 11.7%
-71.8% 
               
1          165 131 79% 46 34 74% 28 50 178%Sa 5965 
2          162 112 69% 100 91 91% 98 54 55%
I 
               
1         206 78 37.90% ~1700 ~988 58% 401 128 32%Sa 1858 
2         630 321 50.90% ~1700 ~784 46% 368 48 13%
-22% 
               
1          471 222 47% 243 81 33% 506 32 6%Sa 3651 
2          686 218 32% ~614 253 41% 430 35 8%
-32.5% 
               
1          460 113 25% 76 55 72% 146 46 32%Sa 1480 
2          415 182 44% 102 30 29% 87 40 46%
-5.5% 
               
1          759 388 51% 117 53 45% 78 13 16%Sa 1770 
2          614 354 58% 105 44 42% 113 21 19%
- 37% 
Transconjugant
s               
1          414 187 45% 368 95 26% 38 32 84%Se 5A1 
2          394 265 67% 301 123 41% 91 59 65%
+18.5% 
               
1          355 101 28% 726 120 16% 115 33 29%Sa 2782-22 
2          416 143 34% 168 14 8% 126 16 13%
-10% 
               
1          224 146 65% 78 35 45% 151 32 21%Se 27A2 
2          278 141 51% 89 25 28% 70 20 28.50%
-33.3% 
               
1          150 77 51% 47 21 45% 87 29 33%Se 30B1 
2          203 87 43% 125 62% 50% 106 50 47%
-7% 
               
1          717 230 32% 99 31 31% 110 40 36%
Sa 22B1 
2          944 363 38% 311 102 33% 117 45 38%
- 2% 
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Table 11. Qualitative Summary of Fitness Cost Assays using Isogenic Pairs of Strains.  “Sa” denotes S. aureus and “Se” S. 
epidermidis. “–” denotes that the analysis was not done.  “NS” denotes difference was not significant. “IC” denotes results were 
inconclusive.  “DT” denotes doubling time.  “R” denotes resistant.  “I” denotes intermediate resistance.  Erythromycin (E), 
Gentamicin (GM), Sulfamethoxazole/Trimethoprim (SXT), Clindamycin (CC), and Ciprofloxacin (CIP).    
 
 
  Fitness Assay Transferable Other Resistances 
 Strain     D.T. Competition Donor Recipient E GM  SXT CC CIP
Sa 1858 NS cost yes -   R  I-->R 
Sa 5965 cost IC yes no I R  I  
Sa 3651 NS cost yes - R R  R R 
Sa1480          cost NS yes - R R R R
Sa 1589          cost cost yes - R R R R
mupA Cures Sa 1770 NS cost yes - R    R   
Se 5A1 cost cost - yes           
Sa 2782-22 NS cost - yes      
Controls ATCC 35556 NS NS - yes         
Se 22B1 TC NS NS - yes  R    
Se 5A1 TC NS benefit - yes  R    
Se 27A2 TC NS cost - yes  R   I 
Sa 2782-22 TC NS cost - yes  R    Transconjugant
s Se 30B1 TC2 NS NS - yes   I R  R 
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CHAPTER 4 
 
DISCUSSION 
 
 Administrative control of mupirocin prescriptions was successful in reducing the 
incidence of high-level and low-level resistance in the S. aureus population at the James H. 
Quillen Veteran’s Affairs Hospital from approximately 30% at its peak to less than 10% 
following implementation (Walker et al. 2004).  The apparent response to relaxed selection on 
mupirocin resistance suggested there was a fitness burden associated with the mupirocin 
resistance.  The observation that both high- and low-level resistance decreased further suggests 
there were costs associated with the acquisition of the mupA gene conferring high-level 
resistance as well as the mutant ileS gene conferring low-level resistance.  However, in the 
current study widespread costs were not immediately evident in naturally-occurring strains when 
the growth rates of high-level and low-level strains of S. aureus and S. epidermidis were 
compared to sensitive strains in vitro.  There was no evidence of a fitness cost associated with 
the mupA gene in either species. However, in S. epidermidis, low-level mupirocin-resistant 
strains were marginally significantly slower growing compared to sensitive and high-level 
resistant strains.  This is consistent with a prior report for low-level mupirocin resistance in S. 
aureus.  Hurdle et al. reported(2004) that chromosomal mutations conferring low-level 
mupirocin resistance in clinical strains were associated with low or no-cost.  Hurdle also 
generated mutations in vitro that did incur a cost and this led to the conclusion that there is 
selective pressure in vivo for those mutations that do not incur a cost. 
  
 While it has been reported that maintaining a plasmid incurs a fitness cost to the bacteria 
(Zünd and Lebek 1980) it has also been reported that the cost is quickly compensated for over 
subsequent generations (Bouma and Lenski 1988, Schrag and Perrot 1996).  There appears to be 
a consensus that there is often a cost associated with antibiotic resistance genes, and that costs 
have been demonstrated both in vivo and in vitro.  However, bacteria can quickly evolve to 
mitigate this cost by means of compensatory mutations, reversion of resistance, selection for no- 
or low-cost mutations, or suppression of resistance under non-selective conditions (Nguyen 
1989, Reynolds 2000, Hurdle et al. 2004).     
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In the current study, comparison of growth rates based on naturally-occurring strains 
highlighted significant inter-strain variation among resistance categories in S. aureus.  All three 
resistance phenotypes showed significant inter-strain variation with the high-level resistant 
strains showing the greatest strain variation (i.e. the slowest growing strain was 91% slower than 
the fastest growing strain).  The extreme magnitude of this strain variation could easily mask a 
fitness cost that may exist.  Consequently, it is necessary to more closely examine costs based on 
comparisons of isogenic pairs of strains (mupA cures and transconjugants) that were generated 
for the purpose of a more direct comparison of the mupA gene.  
 
 It was difficult to cure the high-level mupirocin-resistant S. aureus strains and even more 
difficult to cure the S. epidermidis strains.  Only one S. epidermidis strain was successfully 
cured, suggesting that in most cases the mupA gene is in a non-curable form in this species.  
Curing can be interpreted as strong evidence that the mupA gene was maintained on a plasmid 
(Cookson 1998, Caierao et al. 2006).  Conversely, the inability to cure suggests that the mupA 
gene has been incorporated into the chromosome.  In addition, S. epidermidis reportedly has the 
ability to maintain plasmids more faithfully than S. aureus.  Cookson reported in 1998 that the 
initial discovery of the mupA plasmid was in a form that was easily transferred and cured.  
However, he noted that subsequently discovered mupA plasmids were of varying molecular 
weight and had varying transfer and curing capabilities.  The inability to cure is consistent with 
the fact that administrative control had not eradicated mupirocin resistance from S. epidermidis.  
While the historical data to discern a trend in mupirocin resistance in S. epidermidis, is not 
available, the lack of eradication supports the hypothesis that there is not a cost of resistance in 
S. epidermidis. 
 
  Curing was most successful in S. aureus in strains from era 1, the era that corresponds to 
when mupirocin was first introduced locally.  Although the era 1 sample size is small, there was 
a 63% difference between the curing rate of era 1 and the combine rate for eras 2-4.  The 
difference in cure rates suggests the mupA gene was initially maintained on a plasmid but it has 
since become incorporated into the chromosome or is now on a plasmid harboring essential 
gene(s).  If the mupA gene had changed forms, such a transition would be expected to have been 
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accompanied by a change in the fitness cost.  Specifically, a higher fitness burden would be 
expected to be associated with a plasmid-borne mupA gene because of widespread costs of 
maintaining plasmids. 
  
 Gentamicin resistance was most commonly associated with either the loss through curing 
or gain through filter-mating transfer of the mupA gene.  In S. aureus, gentamicin is often 
maintained on the plasmid pGO1 (Thomas and Archer 1989).  In addition, Morton (1995) 
characterized a pGO1-like plasmid that had transferable mupirocin resistance but had lost 
gentamicin resistance.  Thus, the association of gentamicin and mupirocin resistance further 
suggests the mupA gene was being maintained on a plasmid as well, with either mupA and Gmr 
(encoding gentamicin resistance) carried on the same plasmid or on different plasmids.  
Although prescription rates for gentamicin did not change over time at the VAMC, gentamicin 
resistance experienced a similar decline as mupirocin resistance and both were low in recent 
surveys.  The similar decline of gentamicin resistance supports the hypothesis of a transition in 
the form of the mupA gene and the difference in cure rates. 
 
 While in pure cultures, the doubling times of strains cured of mupirocin resistance was 
significantly lower than their derivatives, the individual costs were, for the most part small, with 
the exception of the 16% cost borne by strain Sa 1589.  However, competition experiments using 
cured derivatives and their respective progenitors demonstrated the potential biological 
importance of even small differences in doubling times.  In S. aureus, four of the five pairs of 
cured derivative-progenitor strains showed a significant reduction (>10%) in the resistant 
population when grown in competition with their respective sensitive derivatives.  Thus, among 
strains capable of curing, there was evidence of a fitness cost associated with the mupA gene.  
Moreover, these analyses demonstrate the competition assay must be considered the more 
sensitive of the two methods of detecting a fitness cost. 
  
 Only two of the five transconjugant isogenic pairs showed evidence of a significant 
fitness cost.  It was expected that a strain that had just received the mupA gene would show the 
strongest evidence of a fitness cost having not had ample time to mitigate the cost through either, 
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compensatory mutations (Schrag and Perrot, 1996), incorporation into the chromosome, or 
reversion of the resistance (Hurdle et al. 2004).  It is not clear why there was not a widespread 
fitness cost associated with the transconjugants.  One possible explanation is that when the mupA 
gene is in a transferable form that compensatory mutations may be maintained on the same 
plasmid thus being co-transferred.  Another possible explanation would be that mupirocin 
resistance is being maintained on a transposon as reported by (Cookson 1998). 
 
 One of the most clinically relevant implications of this study derives from the significant 
strain variation and the low rate of plasmid curing in S. aureus.  Consider the case of a pure-
culture infection.  If the mupA gene is in a non-curable form, there is not opportunity for 
competition with a cured sensitive sub-population.  In a pure culture, a fitness cost becomes 
irrelevant regardless of the selective pressure.  Therefore, only if the mupA gene is curable does a 
fitness cost influence the selective outcomes. 
  
In an alternative scenario, consider mixed strain infections with large strain differences in 
intrinsic growth rates.  For example, Figure 6 highlights the case of a patient infected with both 
strains A and B.  Strain A is an intrinsically fast growing sensitive strain, while B is an 
intrinsically slow growing sensitive strain.  Strain A acquires the mupA gene to generate strain 
AR.  Relative to strain A, strain AR shows a significant fitness cost manifested as a reduction in 
the growth rate of 16%.  However strain AR, although significantly slower than its sensitive 
progenitor, remains significantly faster growing (10%) than strain B.  Therefore, when 
mupirocin is withdrawn or in components of the body not subjected to treatment, the resistant 
strain would outgrow the sensitive strain. 
    
 While there is evidence to suggest that there is a significant fitness cost associated with 
the mupA gene in some cases, the cost is typically small.  Therefore, resolution of the question 
why administrative control was so effective in reducing the incidence of mupirocin resistance 
may lie in quantifying the extent of inter-strain interactions where differences  in growth rates 
influence selective outcomes and also in understanding the genomic location of the mupA gene. 
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Figure 7.  Effect of Strain Variation on Selective Outcomes. “A” represents an intrinsically fast 
growing, naturally-occurring, mupirocin-sensitive S. aureus strain. “AR” represents a mupirocin-
resistant form of “A” following acquisition of the mupA gene. “B” represents a significantly 
slower growing, naturally-occurring, mupirocin-sensitive S. aureus strain compared to strain A 
and AR for which “B” is 24% and 10% slower, respectively. 
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APPENDIX 
Expanded Data Tables 
 
Table 1. Complete Doubling Time Data for Growth Curve Assay. “Sa” signifies S. aureus. “Se” 
signifies S. epidermidis. Era 1: August 1990 – August 1993, Era 2: September 1993 – December 
1995, Era 3: June 1996 – February 1999, Era 4: March 1999 – April 2000, Era 5: May 2000 – 
May 2001, Era 6: November – December 2002. Doubling times are given in minutes for each 
replicate of each strain (R#). Average is the mean of the replicates of each strain. “ND” indicates 
that a third replicate was not done.  
 
   
Doubling 
 Times 
Strain Era 
Resistance 
Category R1 R2 R3 Average 
Naturally-Occurring S. aureus 
Sa 8B1 6 L 99.01 103.09 ND 101.05 
Sa 8C1 6 S 101.01 106.38 ND 103.7 
Sa 44A1 6 H 99.01 108.7 ND 103.86 
Sa 44A3 6 H 89.28 92.59 ND 90.94 
Sa 37A1 6 S 91.74 95.24 ND 93.5 
Sa 7A2 6 S 93.46 94.34 ND 93.9 
Sa 44B1 6 S 88.49 90.91 ND 89.7 
Sa 15A1 6 S 85.47 90.91 ND 88.19 
Sa 5791-1 4 L 86.21 131.58 ND 108.9 
Sa 5588-L 4 H 84.03 80.65 ND 82.34 
Sa 5894-L 4 S 108.7 120.48 ND 114.6 
Sa 1484-H 1 H 86.21 86.21 ND 86.21 
Sa 1754-1 2 H 117.65 128.21 ND 122.93 
Sa 1680-5 2 H 83.33 80 ND 81.67 
Sa 5579-1 4 H 109.08 104.17 ND 106.63 
Sa 1864 2 L 117.65 142.86 ND 130.26 
Sa 2365 2 L 90.91 88.5 ND 89.71 
Sa 5371 3 S 84.75 88.33 ND 86.54 
Sa 1965 2 S 103.09 104.17 ND 103.63 
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Table 1 (continued) 
 
Naturally-Occurring S. epidermidis 
Se 9A1 6 H 105.26 106.38 ND 105.82 
Se 50A1 6 H 97.09 100 ND 98.55 
Se 8B2 6 L 109.89 114.94 ND 112.42 
Se 4C3 6 L 111.11 111.11 ND 111.11 
Se 40A1 6 S 92.59 108.69 ND 100.64 
Se 30B1 6 S 95.24 104.17 ND 99.71 
     mupA Cures       
Sa 1858-8 2 H 153.85 158.73 ND 156.3 
Sa 1858-13 2 S 156.25 149.25 ND 152.75 
       
Sa 5965-10 4 H 106.38 113.64 ND 110.01 
Sa 5965-1 4 S 92.59 101.01 ND 96.8 
       
Sa 3651-9 3 H 98.04 89.29 ND 93.67 
Sa 3651-37 3 S 92.59 89.29 ND 90.94 
       
Sa 1480-1 1 H 89.29 83.33 ND 86.31 
Sa 1480-4 1 S 82.64 80 ND 81.32 
       
Sa 1589-1 1 H 103.09 103.09 ND 103.1 
Sa 1589-48 1 S 77.42 95.24 ND 86.33 
       
Sa 1770-1 2 H 77.52 90.91 ND 84.22 
Sa 1770-24 2 S 76.34 87.72 ND 82.03 
       
Se 17 6 H 101.01 90.09 ND 95.55 
Se 17-10 6 L 109.89 104.17 ND 107.03 
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Table 1 (continued) 
 
Transconjugant
s       
Se 5A1 RF 6 S 136.99 128.21 128.21 131.14 
Se 5A1 TC 6 H 133.33 125 125 127.78 
       
Se 27A2 RF 6 S 128.21 119.05 119.05 122.1 
Se 27A2 TC 6 H 128.21 121.95 121.95 124.04 
       
Sa 2782-22 RF 3 S 104.17 100 99.01 101.06 
Sa 2782-22 TC 6 H 96.15 100 99.01 98.4 
       
Sa 22B1 RF 6 S 104.17 105.26 104.17 104.53 
Sa 22B1 TC 6 H 100 103.09 102.04 101.71 
       
Se 30B1 6 S 95.24 100 100 98.41 
Se 30B1 TC2 6 H 98.04 104.17 98.04 100.08 
Rif/FA Controls       
Se 5A1  3 S 88.5 99.09 ND 93.8 
Se 5A1 RF 3 R 136.99 111.11 ND 124.05 
       
Sa 35556 
ATCC 
Strain S 102.04 108.7 ND 105.37 
Sa 35556 RF 
 ATCC 
Strain R 108.7 108.7 ND 108.7 
       
Sa 2782-22 3 S 89.29 111.11 ND 100.2 
Sa 2782-22 RF 3 R 98.04 104.17 ND 101.11 
  
Table 2. Complete Area under the Curve Data for Growth Curve Assay. “Sa” signifies S. aureus. 
“Se” signifies S. epidermidis. Era 1: August 1990 – August 1993, Era 2: September 1993 – 
December 1995, Era 3: June 1996 – February 1999, Era 4: March 1999 – April 2000, Era 5: May 
2000 – May 2001, Era 6: November – December 2002. Doubling times are given in minutes for 
each replicate of each strain (R#). Average is the mean of the replicates of each strain. “ND” 
indicates that a third replicate was not done. 
 
   
AUC 
 24 hours 
Strain Era 
Resistance 
Category R1 R2 R3 Ave. 
Naturally-Occurring S. aureus 
Sa 8B1 6 L 1133 1121 ND 1127 
Sa 8C1 6 S 1108 1104 ND 1106 
Sa 44A1 6 H 1064 1061 ND 1062.5 
Sa 44A3 6 H 1105 1101 ND 1103 
Sa 37A1 6 S 1133 1191 ND 1162 
Sa 7A2 6 S 1102 1112 ND 1107 
Sa 44B1 6 S 1054 1040 ND 1047 
Sa 15A1 6 S 1114 1105 ND 1109.5 
Sa 5791-1 4 L 918 914 ND 916 
Sa 5588-L 4 H 1090 1122 ND 1106 
Sa 5894-L 4 S 1108 1096 ND 1102 
Sa 1484-H 1 H 1038 1039 ND 1038.5 
Sa 1754-1 2 H 980 984 ND 982 
Sa 1680-5 2 H 1117 1102 ND 1109.5 
Sa 5579-1 4 H 943 949 ND 946 
Sa 1864 2 L 1009 1004 ND 1006.5 
Sa 2365 2 L 1070 1072 ND 1071 
Sa 5371 3 S 1020 1012 ND 1016 
Sa 1965 2 S 1118 1106 ND 1112 
Naturally-Occurring S. epidermidis 
Se 9A1 6 H 1083 1078 ND 1080.5 
Se 50A1 6 H 1114 1103 ND 1108.5 
Se 8B2 6 L 962 950 ND 956 
Se 4C3 6 L 1029 1031 ND 1030 
Se 40A1 6 S 971 954 ND 962.5 
Se 30B1 6 S 916 1065 ND 990.5 
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Table 2 (continued) 
 
mupA Cures       
Sa 1858-8 2 H 1025 1009 ND 1017 
Sa 1858-13 2 S 1013 1034 ND 1023.5 
Sa 5965-10 4 H 871 868 ND 869.5 
Sa 5965-1 4 S 770 752 ND 761 
Sa 3651-9 3 H 1139 1149 ND 1144 
Sa 3651-37 3 S 1060 1087 ND 1073.5 
Sa 1480-1 1 H 1046 1076 ND 1061 
Sa 1480-4 1 S 1105 1109 ND 1107 
Sa 1589-1 1 H 1010 1014 ND 1012 
Sa 1589-48 1 S 895 895 ND 895 
Sa 1770-1 2 H 946 973 ND 959.5 
Sa 1770-24 2 S 974 956 ND 965 
Se 17 6 H 1001 990 ND 995.5 
Se 17-10 6 L 1031 1071 ND 1051 
Transconjugants       
Se 5A1 RF 6 S 889 881 884 884.67 
Se 5A1 TC 6 H 763 766 762 763.67 
Se 27A2 RF 6 S 967 964 950 960.33 
Se 27A2 TC 6 H 977 974 980 977.00 
Sa 2782-22 RF 3 S 999 1030 1017 1015.33 
Sa 2782-22 TC 6 H 998 991 979 989.33 
Sa 22B1 RF 6 S 1118 1105 1076 1099.67 
Sa 22B1 TC 6 H 1063 1045 1071 1059.67 
Se 30B1 6 S 916 924 919 919.67 
Se 30B1 TC2 6 H 917 913 934 921.33 
Rif/FA Controls       
Se 5A1  3 S 1048 1050 ND 1049.00 
Se 5A1 RF 3 R 791 784 ND 787.50 
Sa 35556 
ATCC 
Strain S 977 968 ND 972.5 
Sa 35556 RF 
 ATCC 
Strain R 640 665 ND 652.5 
Sa 2782-22 3 S 1107 1120 ND 1113.5 
Sa 2782-22 RF 3 R 999 1030 ND 1014.5 
  
Table 3. Complete ANOVA Data for Naturally-Occurring S. aureus Strains. 
 
S. aureus Doubling Time 
AUC  
 24 hours 
Source DF SS MS F P Source DF SS MS F P
Resistance 
Category 2 309 155 0.5 0.613 
Resistance 
Category 2 22255 11128 2.19 0.135 
Error 22 6794 309   Error 22 111547 5070   
Total 24 7103    Total 24 133803    
 
 
 
Table 4.  Complete ANOVA Data for Naturally-Occurring S. epidermidis Strains. 
S. epidermidis Doubling Time  
AUC 
24 Hours 
Source DF SS MS F P Source DF SS MS F P
Resistance 
Category 2 196 98 6.87 0.051 
Resistance 
Category 2 16332 8166 6.96 0.075 
Error 4 57.1 14.3   Error 3 3522 1174   
Total 6 253    Total 5 19854    
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Table 5. Strain Variation among Naturally-Occurring S. aureus Resistance Categories Comparing Doubling Times   
Strain Variation of Doubling Times 
among 
S. aureus Resistance Categories    
Source DF SS MS F P Source DF SS MS F P Source DF SS MS F P
Low                 3 1756 585 1.72 0.3 Sensitive 7 1319.6 188.5 13.11 0.001 High 6 2824.9 470.8 25.06
< 
0.001 
Error           4 1358 340  Error 8 115 14.4   Error 7 131.5 18.8   
Total           7 3114 Total 15 1434.6 Total 13 2956.4 
 
 
Table 6.  Strain Variation among Naturally-Occurring S. aureus Comparing Area under the Curve at 24 Hours Data 
Strain Variation of AUC  24 among S. aureus  
Resistance Categories              
Source DF SS MS F P Source DF SS MS F P Source DF SS MS F P
Low                  3 49276.4 16425.5 695.26 <0.001 Sensitive 7 27694 3956 15.41 <0.001 High 12 146124 12177 94.88 <0.001
Error         4 94.5 23.6   Error 8 2055 257   Error 13 1669 128   
Total               7 49370.9  Total 15 29748  Total 25 147792  
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Table 7.  Strain Variation among Resistance Categories in Naturally-Occurring S. epidermidis Comparing Doubling Times 
 
Strain Variation of Doubling Times among  
S. epidermidis Resistance Levels    
Source DF SS MS F P Source DF SS MS F P Source DF SS MS F P
Low                  1 1.7 1.7 0.27 0.657 Sensitive 1 0.9 0.9 0.01 0.928 High 1 52.93 52.93 21.77 0.043
Error              2 12.75 6.38 Error 2 169.5 84.7 Error 2 4.86 2.43
Total                3 14.45 Total 3 170.4 Total 3 57.79
 
 
Table 8. Strain Variation among Resistance Categories in Naturally-Occurring S. epidermidis Comparing Area Under the Curve at 24 
Hours 
 
 
Strain Variation of AUC @ 24 Among 
 S. epidermidis Resistance Levels    
Source DF SS MS F P Source DF SS MS F P Source DF SS MS F P
Low              1 5476 5476 148 0.007 Sensitive 1 784 784 0.14 0.745 High 1 784 784 21.48 0.04
Error                2 74 37 Error 2 11245 5623 Error 2 73 36.5
Total             3 5550  Total 3 12029  Total 3 857  
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